Esperion Therapeutics (ESPR) Projected to Post Earnings on Tuesday

Key Points

• Esperion Therapeutics (ESPR) is set to release its Q2 2025 earnings on August 5th, with expected losses of ($0.17) per share and revenue of $62.55 million.
• In its previous quarter, Esperion reported a loss of ($0.21) per share, missing estimates, but its revenue of $65 million exceeded analyst expectations of $54.97 million.
• Analysts have mixed ratings for ESPR, with a consensus rating of "Moderate Buy" and a price target ranging from $3.00 to $16.00, indicating differing outlooks on the stock's potential.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $62.55 million for the quarter.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). The business had revenue of $65.00 million for the quarter, compared to the consensus estimate of $54.97 million. Esperion Therapeutics had a negative return on equity of 0.91% and a negative net margin of 59.03%. On average, analysts expect Esperion Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Esperion Therapeutics Price Performance

Shares of ESPR traded down $0.05 during mid-day trading on Friday, hitting $1.38. 550,961 shares of the company's stock were exchanged, compared to its average volume of 4,716,892. The company has a market cap of $272.53 million, a PE ratio of -1.72 and a beta of 0.70. Esperion Therapeutics has a 52 week low of $0.69 and a 52 week high of $3.94. The company has a 50-day simple moving average of $1.14 and a 200 day simple moving average of $1.35.

Hedge Funds Weigh In On Esperion Therapeutics

An institutional investor recently bought a new position in Esperion Therapeutics stock. Jones Financial Companies Lllp bought a new stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 192,743 shares of the biopharmaceutical company's stock, valued at approximately $278,000. Jones Financial Companies Lllp owned approximately 0.10% of Esperion Therapeutics at the end of the most recent quarter. Institutional investors own 47.39% of the company's stock.

Analyst Ratings Changes

ESPR has been the subject of several research reports. The Goldman Sachs Group decreased their price target on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. HC Wainwright reaffirmed a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a research note on Tuesday, June 17th. Finally, Needham & Company LLC decreased their price target on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $7.00.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.